May 2, 2019
Dr. Michela Gallagher, founder and CEO of AgeneBio, Inc. and professor at Johns Hopkins University, was honored at the luncheon for her work advancing treatments for Alzheimer's disease. Dr. Gallagher received the inaugural Estelle Gelman Award for Innovation in Drug Discovery for her groundbreaking research that holds the potential to yield the first drug to slow the progression of symptoms associated with mild cognitive impairment due to Alzheimer's disease.
January 29, 2019
Michela Gallagher, CEO of AgeneBio, and her staff have given themselves a big challenge – to develop the first and only therapeutic targeting brain network imbalance and potentially the first therapeutic to slow progression to and delay the onset of Alzheimer’s…
January 17, 2019
AGB101 is the first investigational therapeutic that targets the reduction of hippocampal overactivity. The study evaluates both Primary and Secondary Endpoints to measure cognitive and functional efficacy. Secondary imaging endpoints will include measures of neurodegeneration. BALTIMORE, MD (January 17, 2019)…
October 9, 2018
– NIH awards an expected $16 million to support Phase 3 pivotal clinical trial of AGB-101, a once-a-day treatment to slow progression in Mild Cognitive Impairment due to Alzheimer’s disease. – NIH awards follow on funding from the Blueprint Neurotherapeutics…
April 30, 2018
Gallagher highlights the groundbreaking clinical trial, HOPE4MCI, which could slow progression from Mild Cognitive Impairment to Alzheimer’s dementia LOS ANGELES, April 30, 2018 — Today, AgeneBio Founder Dr. Michela Gallagher participated in a panel discussion at the Milken Global Conference Alzheimer’s Disease: Rewriting the Playbook.…
February 28, 2018
Emerging Therapeutics Focus on Hippocampal Hyperactivity in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Baltimore, MD, February 28, 2018 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that founder and Chief…
February 28, 2018
Focus on Research Targeting Hippocampal Hyperactivity in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Baltimore, MD, February 28, 2018 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that founder and Chief…
September 19, 2017
Enrollment of First Patients Expected in Q1 2018 Baltimore, MD, September 19, 2017 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced it has been awarded a grant from the National Institute on Aging…
September 13, 2017
Grant to support novel GABAA program targeting hippocampal overactivity that leads to neurodegeneration and cognitive decline in Alzheimer’s disease patients Baltimore, MD, September 13, 2017 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced…
July 24, 2017
Founder and CSO Michela Gallagher, PhD co-chaired a featured symposium, “The Two-Way Street Linking B-Amyloid, Tau and Neural Activity” and presented “Age-Related Network Dysfunction: Contributions of Neural Activity to Risk for Late Onset Alzheimer’s Disease.” Details available here.
